NCT06941480View on ClinicalTrials.gov

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2030

Study Completion Date

May 31, 2030

Conditions
Neuroendocrine Tumor of the LungNeuroendocrine Carcinoma of LungNeuroendocrine CarcinomaNeuroendocrine Carcinoma of Prostate
Interventions
DIAGNOSTIC_TEST

PET/CT

Participants will undergo 89Zr-DFO-SC16.56 Ab PET/CT

BIOLOGICAL

177Lu-DTPA-SC16.56

177Lu-DTPA-SC16.56, to be administered within 2 weeks of the PET/CT

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack

07920

Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER